Vasoactive intestinal peptide (VIP) exhibits bronchodilatory, vasodilatory, and immunomodulatory activities. VIP increases levels of IL-10, Foxp3, and TGF-β in vivo and prevents LPS-induced expression of IL-6 and MCP-1 in vitro. VIP appears to play a significant role in respiratory inflammation. VIP activates VPAC1/2 receptors.
| Purity | ≥95% |
|---|---|
| Formula | C147H239N43O42S2 |
| Formula Wt. | 3344.93 |
| Synonym | VIP, guinea pig |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | V3360 Info Sheet PDF |
|---|
Hauk V, Azzam S, Calo G, et al. Vasoactive intestinal Peptide induces an immunosuppressant microenvironment in the maternal-fetal interface of non-obese diabetic mice and improves early pregnancy outcome. Am J Reprod Immunol. 2014 Feb;71(2):120-30. PMID: 24405265.
Fraccaroli L, Grasso E, Hauk V, et al. Contribution of Vasoactive Intestinal Peptide to Immune Homeostasis in Trophoblast-Maternal Leukocyte Interaction under LPS Stimulation. Neuroimmunomodulation. 2014;21(1):21-30. PMID: 24135863.
Mathioudakis A, Chatzimavridou-Grigoriadou V, Evangelopoulou E, et al. Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics. Hippokratia. 2013 Jan;17(1):12-6. PMID: 23935337.
